COPD 患者认知功能障碍及血浆 NGAL、ET-1 水平变化的研究

目的 探讨慢性阻塞性肺疾病（COPD）患者认知障碍及血浆中性粒细胞明胶酶相关脂质运载 蛋白（NGAL）及内皮素-1（ET-1）水平变化的意义。方法 选取COPD 患者（COPD 组）312 例，同期 匹配健康查体者（对照组）89 例，比较认知功能障碍及合并认知功能障碍与否患者的NGAL、ET-1 水平。 结果 与对照组相比，COPD 组视空间执行能力、注意力、延时回忆及MoCA 总分较低（P <0.05）。COPD 组血浆NGAL、ET-1 水平高于对照组（P <0.05）。对照组有认知功能障碍患者血浆NGAL、ET-1 水平高于 无认知功能障碍者（P <0.05）。COPD 组有认知功能障碍者血浆NGAL、ET-1 水平高于无认知功能障碍者 （P <0.05）。结论 COPD 患者认知功能损害较正常对照人群增加，合并认知障碍人群血浆NGAL 及ET-1 升高。

Cognitive impairment assessment and changes of plasma NGAL and ET-1 levels in patients with COPD

Objective To investigate the cognitive impairment and the plasma levels of neutrophil gelatinase associated lipocalin (NGAL) and endothelin-1 (ET-1) in the patients with chronic obstructive pulmonary disease (COPD) . Methods In this study, 312 cases in COPD group and 89 healthy people in control group were enrolled. The subjects in both groups received the MoCA (Montreal Cognitive Assessment Scale) assessment and detection of plasma levels of NGAL and ET-1. Results Compared with the control group, the scores of visual spatial executive ability, attention and delayed recall and the total scores of MoCA were lower in the COPD group (P < 0.05). The plasma levels of NGAL and ET-1 in the COPD group were higher than those in the control group (P < 0.05). In the control group, the plasma levels of NGAL and ET-1 in the people with cognitive impairment were higher than those in the people without cognitive impairment (P < 0.05). In the COPD group, the plasma levels of NGAL and ET-1 in the patients with cognitive dysfunction were higher than those in the patients without cognitive impairment (P < 0.05). Conclusions Compared with normal controls, cognitive impairment in the COPD patients is more severe, and the plasma levels of NGAL and ET-1 are significantly higher in the patients with cognitive impairment.